Non-hormonal treatments for hot flashes: the full menu

If you cannot or would rather not take estrogen, you still have real options for hot flashes. The Menopause Society’s 2023 position statement sorts them into those with good, consistent evidence (CBT, clinical hypnosis, SSRIs/SNRIs, gabapentin, fezolinetant), those with weaker support (oxybutynin, weight loss, stellate ganglion block), and a long list that is not recommended. This guide walks the whole menu so you can go to your clinician with a short list.

What counts as “non-hormonal”

A non-hormonal treatment reduces hot flashes without supplying estrogen or progestogen. That includes prescription drugs originally developed for other conditions (antidepressants, gabapentin, oxybutynin), newer drugs designed specifically for hot flashes (fezolinetant, elinzanetant), and structured behavioral therapies (cognitive behavioral therapy, clinical hypnosis).

Hot flashes start in the hypothalamus, where a cluster of neurons (the KNDy neurons) becomes overactive as estrogen falls and disrupts the brain’s temperature set point. Each treatment on the menu dampens that system in a different way, which is why side effects and strengths differ.

Hormone therapy remains the most effective treatment, and the position statement says it should be considered for women within 10 years of their final period who have no contraindications. Non-hormonal options matter most for women with estrogen-sensitive cancers, clotting or cardiovascular history, or a personal preference to avoid hormones. If you are still unsure where you are in the transition, start with what perimenopause is.

FDA-approved status, stated plainly

Three non-hormonal drugs are FDA-approved specifically for moderate to severe vasomotor symptoms:

• Paroxetine mesylate 7.5 mg (Brisdelle), approved in 2013. This low dose is not approved for depression or any psychiatric condition.
• Fezolinetant (Veozah), approved May 12, 2023, a neurokinin 3 receptor antagonist.
• Elinzanetant (Lynkuet), approved October 24, 2025, a dual neurokinin 1 and 3 receptor antagonist.

Everything else below (other SSRIs and SNRIs, gabapentin, oxybutynin) is prescribed off-label. Off-label use is legal and common, but it means the hot flash dose and duration were established in independent trials rather than through FDA review.

Prescription options and what the trials show

Fezolinetant. In the SKYLIGHT 1 and 2 trials, women averaged 10 to 12 moderate to severe hot flashes a day. At week 12, fezolinetant 45 mg reduced daily frequency by about 2.5 more episodes than placebo (placebo itself fell by 4 to 5 a day). The FDA added a boxed warning for rare serious liver injury in December 2024, with required blood tests.

Elinzanetant. In OASIS 1 and 2, elinzanetant 120 mg reduced daily hot flash frequency by about 3.2 more episodes than placebo at week 12, and improved sleep disturbance scores. It was approved after the 2023 position statement was written, so the statement lists it as “in development.”

SSRIs and SNRIs. The position statement describes mild to moderate improvement, with hot flash reductions ranging from 25% to 69% across trials. In the MsFLASH trial of 339 women, venlafaxine 75 mg cut frequency by 47.6% versus 28.6% for placebo; low-dose estradiol cut it by 52.9%. Paroxetine, escitalopram, citalopram, venlafaxine, and desvenlafaxine have positive large trials; sertraline and fluoxetine did not reach significance and are not recommended.

Gabapentin. At 900 mg a day, gabapentin cut hot flash frequency 45% versus 29% for placebo in a 59-woman trial; at 2,400 mg it matched conjugated estrogen in a 60-woman trial. Drowsiness is the main side effect, which makes bedtime dosing useful for night sweats.

Oxybutynin. An overactive-bladder drug with anticholinergic effects. In a 150-woman trial (two-thirds on tamoxifen or an aromatase inhibitor), oxybutynin 5 mg twice daily reduced weekly hot flash frequency by 7.5 episodes versus 2.6 for placebo. Dry mouth and urinary difficulty were common. The position statement rates it Level I-II and flags that long-term anticholinergic use may be associated with cognitive decline in older adults.

Not recommended: clonidine (modest effect, many side effects), pregabalin (side effects, controlled substance, one trial), and suvorexant (one small study).

Behavioral options

Cognitive behavioral therapy has Level I support. In the MENOS trials, group or self-help CBT reduced how much hot flashes were rated as a problem, with gains lasting to 26 weeks. CBT reliably reduces bother and sleep disruption more than it reduces the number of flashes.

Clinical hypnosis also has Level I support. In a 187-woman trial with an active control, five weekly sessions reduced self-reported hot flash frequency 74% versus 17%.

Not recommended: paced respiration (Level I evidence of no benefit), mindfulness-based stress reduction, relaxation, yoga, exercise, cooling techniques, and avoiding triggers. These may help well-being, but trials do not show they reduce hot flashes beyond placebo.

Supplements, acupuncture, and procedures

The position statement does not recommend supplements or herbal remedies, soy foods or extracts, the soy metabolite equol, cannabinoids, acupuncture, or chiropractic care for hot flashes. Placebo improvement in hot flash trials runs 20% to 66%, so uncontrolled reports of benefit are hard to interpret.

Two options get a qualified “may be considered” (Level II-III): weight loss, which has reduced hot flashes in behavioral trials, especially earlier in the transition; and stellate ganglion block, an injection near neck nerves, where one sham-controlled trial showed a 21% reduction in physiologically measured flashes. The statement notes it is a procedure with its own risks and should be weighed carefully.

How the main options compare

Option	FDA-approved for hot flashes	Typical effect vs placebo	Main drawbacks
Fezolinetant 45 mg	Yes (2023)	About 2.5 fewer flashes/day at week 12	Liver blood tests, boxed warning, cost
Elinzanetant 120 mg	Yes (2025)	About 3.2 fewer flashes/day at week 12	Newest option, least long-term data
Paroxetine 7.5 mg	Yes (2013)	0.9 to 1.7 fewer flashes/day at week 12 (median)	Avoid with tamoxifen; SSRI class warnings
Other SSRIs/SNRIs	No (off-label)	Mild to moderate; venlafaxine about 1.8 fewer/day	Nausea, dry mouth, sexual side effects
Gabapentin 900 to 2,400 mg	No (off-label)	Roughly 35 to 38% greater reduction in score than placebo in pooled trials	Drowsiness, dizziness
Oxybutynin 2.5 to 5 mg twice daily	No (off-label)	About 5 fewer flashes/week beyond placebo	Dry mouth, urinary difficulty, cognitive concern long term
CBT	Not applicable	Reduces bother and sleep disruption, less effect on count	Access, time commitment
Clinical hypnosis	Not applicable	Large reduction in one active-controlled trial	Finding trained providers

Choosing with your clinician

Match the option to your whole picture. If night sweats and sleep are the main problem, gabapentin at bedtime or CBT for insomnia address both. If you also have low mood or anxiety, an SSRI or SNRI may do double duty. If you take tamoxifen, avoid paroxetine and fluoxetine. If you want a drug built for hot flashes and can manage the lab schedule, fezolinetant or elinzanetant are the most targeted.

A clinician who sees a lot of menopause will know these trade-offs; here is how to find a menopause specialist or search OB-GYNs near you. Before the visit, our symptom check can help you summarize what is bothering you most.

Questions to bring

• Am I a candidate for hormone therapy, and if not, why?
• Which non-hormonal option fits my other symptoms (sleep, mood, bladder)?
• What interactions matter with my current medications, especially tamoxifen or CYP1A2 inhibitors?
• How long should I try it before we judge whether it is working?
• What is the plan if the first choice does not help or has side effects?